. 2021 May 13;13(10):2352. doi: 10.3390/cancers13102352

Table 1.

Characteristics of NSCLC patients in studies included in the meta-analysis.

Trial	Comparison	Total N Patients	Male	Age	Histology	Setting	PD-L1 < 1%	PD-L1 > 1%	Objective Response Rate	Comparative Regimens	Assessed Study Quality
Trial	Comparison	Total N Patients	(%)	Age	Histology	Setting	PD-L1 < 1%	PD-L1 > 1%	Objective Response Rate	Comparative Regimens	Assessed Study Quality
Phase III RCT
Antonia et al. [14,15]	ICI-RT vs. RT alone	237	70.1	64	Adeno: 387 Squamous: 326	Advanced	148	303	365	RT	Low risk of bias ****
Antonia et al. [14,15]	ICI-RT vs. RT alone	476	70.1	64	Adeno: 387 Squamous: 326	Advanced	148	303	365	RT + DURVA	Low risk of bias ****
Theelen et al. [16]	ICI-RT vs. ICI alone	40	56.6	<65:43	Adeno: 67 Squamous: 9	Metastatic	43	31	26	PEMBRO	Low risk of bias ****
Theelen et al. [16]	ICI-RT vs. ICI alone	36	56.6	≥65:33	Adeno: 67 Squamous: 9	Metastatic	43	31	26	PEMBRO + RT	Low risk of bias ****
Welsh el al. [20]	ICI-RT vs. ICI alone	40	63.7	66	Adeno: 61 Squamous: 17	Metastatic	19	32	17	PEMBRO	Low risk of bias ****
Welsh el al. [20]	ICI-RT vs. ICI alone	40	63.7	66	Adeno: 61 Squamous: 17	Metastatic	19	32	17	PEMBRO + RT	Low risk of bias ****
NCDB
Foster et al. [19] *	ICI-RT vs. RT alone	3344	52.2	64.5	Adeno: 2825 Squamous: 746	Metastatic	n.r.	n.r.	n.r.	RT	7/9 ***
Foster et al. [19] *	ICI-RT vs. RT alone	228	52.2	64.5	Adeno: 2825 Squamous: 746	Metastatic	n.r.	n.r.	n.r.	RT + ICI	7/9 ***
Bates el al. [18] **	ICI-RT vs. ICI alone	3621	53.2	<65:3165	Adeno: 3472 Squamous: 434	Metastatic	n.r.	n.r.	n.r.	ICI	7/9 ***
Bates el al. [18] **	ICI-RT vs. ICI alone	285	53.2	≥65:3218	Adeno: 3472 Squamous: 434	Metastatic	n.r.	n.r.	n.r.	RT + ICI	7/9 ***
Subgroup analysis of RCT
Shaverdian et al. [17]	ICI-RT vs. ICI alone	42	51.5	65.6	Adeno: 78 Squamous: 19	Advanced	11	55	19	PEMBRO	Unclear risk of bias ****
Shaverdian et al. [17]	ICI-RT vs. ICI alone	55	51.5	65.6	Adeno: 78 Squamous: 19	Advanced	11	55	19	RT + PEMBRO	Unclear risk of bias ****

Legend: N = number; NCDB = National Cancer Database; NSCLC = non-small cell lung cancer; ICI = immunotherapy; DURVA = durvalumab; PEMBRO = pembrolizumab; n.r. = not reported; RT= radiotherapy; RCT = randomized controlled trial. * data related to patients treated with immunotherapy with no radiotherapy or with stereobody radiotherapy; ** data related to patients treated with immunotherapy with no radiotherapy or with stereobody radiotherapy; *** Quality assessed with nine-star Newcastle-Ottawa Scale (NOS); **** Quality assessed with Cochrane Collaboration’s risk of bias tool.